B220 |
Catalog No.GC33986
One-Click Copy Product Info
|
B220 is an antiviral agent which can inhibit the growth of HSV-1, HSV-2 and human cytomegalovirus (CMV).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 112228-65-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
B220 is an antiviral agent which can inhibit the growth of HSV-1, HSV-2 and human cytomegalovirus (CMV).
B220 is an antiviral agent which can inhibit the growth of HSV-1, HSV-2 and human cytomegalovirus (CMV)[1]. B220 inhibits neutrophil release of reactive oxygen species, as well as intracellular generation of reactive oxygen species. The inhibition is not achieved through direct oxygen radical scavenger activity of B220, and B220 has no immediate effects on the activity of the assembled oxidase. The neutrophil capability to phagocytose fluorescein-labeled opsonized yeast cells is reduced by B220. Cells preincubated with B220 (10 µg/mL) and then stimulated with the formylated peptide fMLP mobilize fewer C3 receptors on their surface than the control cells[2].
[1]. Mohammed Homman, et al. Pharmaceutical formulation of B220 for topical treatment of herpes. EP 2489354 A1. [2]. Harbecke O, et al. The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline inhibits neutrophil production of reactive oxygen species. J Leukoc Biol. 1999 Jun;65(6):771-7.
Cell experiment: | Cells preincubated with or without B220 are stimulated with N-formylmethionyl-leucyl-phenylalanine (fMLP) for 5 min and then fixed in paraformaldehyde [4% w/v in phosphate-buffered saline (PBS); 30 min on melting ice]. For detection of CR3, 10 µL of conjugated mAb is added to a cell pellet (approximately 100 µL) of 106 cells. The mixture is incubated for 30 min on ice and then washed twice with PBS. The amount of antibody bound is examined by flow cytometry. The release of vitamin B12-binding protein is assayed after activation of the cells with fMLP for 5 min using the cyanocobalamin technique[2]. |
References: [1]. Mohammed Homman, et al. Pharmaceutical formulation of B220 for topical treatment of herpes. EP 2489354 A1. | |
| Cas No. | 112228-65-6 | SDF | |
| Canonical SMILES | CC1=C(C)C=C2N=C3C(N(CCN(C)C)C4=C3C=CC=C4)=NC2=C1 | ||
| Formula | C20H22N4 | M.Wt | 318.42 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1405 mL | 15.7025 mL | 31.4051 mL |
| 5 mM | 628.1 μL | 3.1405 mL | 6.281 mL |
| 10 mM | 314.1 μL | 1.5703 mL | 3.1405 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)